Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06056908
Other study ID # P00020466
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 19, 2016
Est. completion date January 1, 2090

Study information

Verified date September 2023
Source Boston Children's Hospital
Contact Akiko Shimamura, MD, PhD
Email akiko.shimamura@childrens.harvard.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records and to bank biological samples with the goal of understanding SDS/SDS-Like diseases to develop better treatments and improve the health of patients with these conditions.


Description:

The Shwachman-Diamond Syndrome Registry (SDSR) is dedicated to accelerating research and treatment for SDS to improve survival and quality of life for all patients with the disease. The SDSR is run jointly by Boston Children's Hospital and Cincinnati Children's Hospital Medical Center. Objective and Aims: The long term goals of the Registry are to improve diagnosis, inform medical management, and to develop better treatments for SDS and SDS-Like disorders. To achieve these objectives, the Registry has the following specific aims: - Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like disorders. - Investigate the molecular and genetic pathogenesis of SDS/SDS-Like conditions and their complications such as marrow failure and clonal evolution. - Identify new genes causing SDS/SDS-Like conditions. - Provide education on the diagnosis, medical management and treatment of SDS for patients, families and the medical/scientific community. Methods: The SDSR collects information from medical records and biological samples. Samples for the SDSR are collected when they are obtained for clinical care so that no extra visits or procedures are needed. These samples may include blood, bone marrow, skin cells, saliva, or discards from other clinical procedures. Family members may also contribute blood samples. All information obtained by the SDSR is housed on a secure, HIPAA-compliant database. No personal information is shared outside of the study team.


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date January 1, 2090
Est. primary completion date January 1, 2090
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Shwachman Diamond syndrome, Shwachman-Diamond Syndrome-Like conditions, or a genetically undefined condition that shares clinical features with Shwachman Diamond Syndrome. - Biallelic mutations in SBDS, or pathogenic mutations in DNAJC21, EFL1, or SRP54 OR - Shwachman-Diamond Syndrome defined clinically OR - Clinically suspected Shwachman-Diamond Syndrome OR - Phenotypic features suggestive of SDS OR - Parents, siblings, and other blood relatives of any age, living and deceased, of patients with SDS or SDS-Like conditions are eligible for this study Exclusion Criteria: • Patients with other diagnosed causes of bone marrow failure, exocrine pancreatic insufficiency and cancer predisposition will be excluded.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States Boston Children's Hospital Boston Massachusetts
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Sponsors (2)

Lead Sponsor Collaborator
Boston Children's Hospital Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like conditions. The SDSR will collect clinical information regarding SDS and SDS-Like conditions. The goal is to understand the natural history, treatment outcomes and complications of these rare disorders in order to improve diagnosis, medical management, and treatment. 50 years
Primary Investigate the molecular and genetic pathogenesis of SDS/SDS-Like condtions and their complications such as marrow failure and clonal evolution. The SDSR will coordinate a repository of blood, cord blood, bone marrow, saliva, skin fibroblast, and tumor samples and cell lines from patients with SDS and SDS-Like conditions for basic science studies of molecular and genetic pathways causing these disorders and their complications. We will also study how genetic/molecular pathways may be targeted or corrected for the development of new therapies. To this end, we will create immortalized cell lines including EBV-transformed lymphoblasts, immortalized fibroblasts, and induced pluripotent stem cells. These cell lines will provide a renewable source of rare patient-derived material for these studies. 50 years
Primary Identify new genes causing SDS/SDS-Like conditions The SDSR will sequence DNA from patient samples to try to identify new genes that are involved in SDS/SDS-like phenotypes. 50 years
Primary Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community. The SDSR will disseminate information through the study website, conferences, and other scientific publications. 50 years
See also
  Status Clinical Trial Phase
Recruiting NCT02179359 - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT00176852 - Stem Cell Transplant for Hemoglobinopathy Phase 2/Phase 3
Completed NCT00176878 - Stem Cell Transplant for Bone Marrow Failure Syndromes Phase 2/Phase 3
Completed NCT01917708 - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Phase 1
Completed NCT00499070 - Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment N/A
Recruiting NCT04275479 - Diabetes/ Endocrine Surveillance in SDS
Completed NCT01529827 - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Recruiting NCT04965597 - Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Phase 2

External Links